Neurosense Therapeutics Ltd Stock Analysis
| NRSNW Stock | USD 0.25 0.13 34.21% |
NeuroSense Therapeutics Ltd is overvalued with Real Value of 0.17 and Hype Value of 0.18. The main objective of NeuroSense Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what NeuroSense Therapeutics Ltd is worth, separate from its market price. There are two main types of NeuroSense Therapeutics' stock analysis: fundamental analysis and technical analysis.
The NeuroSense Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. NeuroSense Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. NeuroSense Stock trading window is adjusted to America/New York timezone.
NeuroSense |
NeuroSense Stock Analysis Notes
The company recorded a loss per share of 0.94. NeuroSense Therapeutics had not issued any dividends in recent years. NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. Neurosense Therapeutics is traded on NASDAQ Exchange in the United States. To find out more about NeuroSense Therapeutics Ltd contact Alon BenNoon at 972 9 799 6183 or learn more at https://www.neurosense-tx.com.NeuroSense Therapeutics Investment Alerts
| NeuroSense Therapeutics is way too risky over 90 days horizon | |
| NeuroSense Therapeutics has some characteristics of a very speculative penny stock | |
| NeuroSense Therapeutics appears to be risky and price may revert if volatility continues | |
| NeuroSense Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NeuroSense Therapeutics Ltd has accumulated about 994 K in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.13. | |
| NeuroSense Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: NeuroSense Therapeutics Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC Form 6 K - Marketscreener.com |
NeuroSense Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.18) | (3.34) | |
| Return On Capital Employed | 42.58 | 44.70 | |
| Return On Assets | (3.18) | (3.34) | |
| Return On Equity | 5.39 | 5.66 |
Management Efficiency
The company has return on total asset (ROA) of (1.5079) % which means that it has lost $1.5079 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.9484) %, meaning that it generated substantial loss on money invested by shareholders. NeuroSense Therapeutics' management efficiency ratios could be used to measure how well NeuroSense Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NeuroSense Therapeutics' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 5.66 in 2024, whereas Return On Tangible Assets are likely to drop (3.34) in 2024. At this time, NeuroSense Therapeutics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 23.4 K in 2024, whereas Other Current Assets are likely to drop slightly above 97 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.14) | (0.13) | |
| Tangible Book Value Per Share | (0.14) | (0.13) | |
| Enterprise Value Over EBITDA | (0.77) | (0.81) | |
| Price Book Value Ratio | (5.71) | (5.43) | |
| Enterprise Value Multiple | (0.77) | (0.81) | |
| Price Fair Value | (5.71) | (5.43) | |
| Enterprise Value | 12.3 M | 12.9 M |
Leadership effectiveness at NeuroSense Therapeutics Ltd is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 1.565 | Return On Assets (1.51) | Return On Equity (4.95) |
Technical Drivers
As of the 14th of December 2024, NeuroSense Therapeutics secures the Mean Deviation of 17.85, risk adjusted performance of 0.129, and Downside Deviation of 29.31. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NeuroSense Therapeutics, as well as the relationship between them. Please verify NeuroSense Therapeutics jensen alpha and semi variance to decide if NeuroSense Therapeutics Ltd is priced some-what accurately, providing market reflects its recent price of 0.25 per share. As NeuroSense Therapeutics appears to be a penny stock we also strongly suggest to check its total risk alpha numbers.NeuroSense Therapeutics Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. NeuroSense Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for NeuroSense Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
NeuroSense Therapeutics Predictive Daily Indicators
NeuroSense Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NeuroSense Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.66 | |||
| Day Median Price | 0.25 | |||
| Day Typical Price | 0.25 | |||
| Price Action Indicator | (0.07) | |||
| Period Momentum Indicator | (0.13) |
NeuroSense Therapeutics Forecast Models
NeuroSense Therapeutics' time-series forecasting models are one of many NeuroSense Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary NeuroSense Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About NeuroSense Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how NeuroSense Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling NeuroSense shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as NeuroSense Therapeutics. By using and applying NeuroSense Stock analysis, traders can create a robust methodology for identifying NeuroSense entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding NeuroSense Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
| All Next | Launch Module |
Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.